CLL Next Generation Reversible BTK Inhibitor, For Overcoming Acquired Resistance to Irreversible BTK Inhibitors

277 views
November 5, 2018
Oral Abstract CLL 200: LOXO-305
0 Comments
Login to view comments. Click here to Login